

Small molecule drug screen identifies FDA-approved drugs capable of enhancing neutrophil responses to the invasive human fungal pathogen, *Candida albicans*

Michael K. Mansour, MD, PhD

Associate Professor of Medicine, Harvard Medical School

Transplant Infectious Diseases and Immunocompromised Host Service

Massachusetts General Hospital, Boston, MA USA

MHSRS

August 2026



Disclosures


1. Vericel - *medical advisory board*
2. GenMark/Roche Diagnostics - *medical and scientific advisory board*
3. Neutrophil therapeutics - *patents held*
4. UpToDate - *medical writer*
5. ThermoFisher Scientific – *unrestricted grant*
6. Opinions are my own

The Need


1. Rising antimicrobial resistance across all sectors and global sites
2. Lack of antimicrobial development
3. Ceiling effect of antimicrobial agents

Created a delta gap to cure
Solution is HOST HARDENING

Devastating consequences of neutropenia



Neutrophils have multiple killing mechanism



Phagocytosis

Neutrophil Oxygen Species

Degradative Enzymes



MASSACHUSETTS
GENERAL HOSPITAL




MANSOUR LAB
Empowering Immunity



HARVARD
MEDICAL SCHOOL

Clues that Neutrophils have preferential recognition



MASSACHUSETTS
GENERAL HOSPITAL





MANSOUR LAB
Empowering Immunity




HARVARD
MEDICAL SCHOOL

Swarming

Poly-l-lysine/Zetag




Printing large scale arrays of live pathogen targets




Neutrophil swarming restricts *C. albicans* growth




C. albicans plus neutrophils




C. albicans Alone




Neutrophil Swarming




C. albicans Alone



Neutrophil swarming in the presence of inhibitors



Healthy neutrophils



Healthy neutrophils + inhibitors

Pilot study - *demographics*


- Transplants:
 1. Renal
 2. Liver
 3. HSCT
- Presenting for outpatient visit 2 months after surgery or BMT
- Feeling well
- Immunosuppression tapered down




Natalie Alexander



Nico Barros




Transplant PMN have swarming dysfunction



Rapid multiparametric neutrophil profiling


MultiParametric Assay (MPA)



Timmer KD, Mansour MK. Cells. 2023 Feb 25;12(5):743



Rapid multiparametric neutrophil profiling

MultiParametric Assay (MPA)



Rapid multiparametric neutrophil profiling

MultiParametric Assay (MPA)




High-Throughput Screening of Small Molecules for Modulators of the Neutrophil Response




The Screen

- We conducted a high-throughput, cell-based screen of 2,816 small molecules on healthy donor neutrophils
- We tested a library approved by governing agencies (FDA, EMA, HMA, etc.) or pharmacopoeia (USP, BP, EP, etc.)
- Approximately 3,000 compounds
- Bioactivity and safety have been confirmed in clinical trials.



Workflow



Equipment

Acoustic Dispenser




Automated Solution Loader




Representative screen plate

- An experimental plate containing potential enhancers and potential inhibitors.




Compound selection

After testing 2,816 compounds in duplicate, 48 compounds had statistically significant z-scores




Compound selection

42 out of 48 compounds validated during cherry-pick




Compound selection

33 compounds had substantial response when normalized to our positive controls




Compound selection

After excluding known augmenters of ROS (i.e., antioxidants), 16 compounds were identified








Compound selection

Of these 16 compounds, 8 appear to be working acting on a similar pathway




Validation using multiparametric flow assay



Untreated
 Enhancers
 Inhibitors

ROS Production


ROS production at MOI 2



Conclusion

1. Neutrophil dysfunction
 - **Neutrophils are incredibly dynamic cells with multiple functions**
 - **Swarming**
 - **MPA**
 - **In vivo assays**
 - **Heterogeneity**
2. Clinical cohorts
 - **Functional differences exist in multiple patient cohorts**
3. Therapeutic implications
 - **Augmentation – drug screen**
 - **Drug screen identifies several small molecules**
 - **Cytokines**
 - **Cell therapy?**


Peripheral Blood Neutrophils





Cell Therapy for Ionizing Radiation or MDR Infection



C. albicans
+ saline only



C. albicans
+ engineered
neutrophils



Acknowledgements

Mansour Lab

Hailey Warren
Sebastian Jusuf
Tim Neumeister
Elizabeth Trull
Jelena Milosevic

4DBio³/USU

Vince Ho, MD, MBA

Orion Furmanski
Shweta Singh
Mayah Lovell
Armando Estrada

BioMEMS

Daniel Irimia

Alex Hopke

Harvard CRM

David Sykes
David Scadden

MGH Transplant Center


Broad Institute of MGH, MIT and Harvard



National Institute
of Allergy and
Infectious Diseases



Partners Innovation Award



USU Uniformed
Services University

www.mansourlab.com



MANSOUR LAB
Empowering Immunity



MASSACHUSETTS
GENERAL HOSPITAL



MANSOUR LAB
Empowering Immunity



HARVARD
MEDICAL SCHOOL